Abstract
Introduction
Incidence of prostate cancer in the seven major markets will be just over
422,000 in 2009, indicating high patient potential for drug developers to
invest in. There are currently 136 agents in development for prostate cancer,
two-thirds of which are novel targeted therapies or immunotherapies.
Collectively, the nine drugs in late-phase development are forecast to achieve
$2,780m in sales by 2018.
Scope of this research
- Examination of the prostate cancer pipeline with in-depth clinical and
commercial profiles of Phase III candidates
- Seven major pharmaceutical market sales forecasts for Phase III pipeline
products through to 2018 with product-specific assumptions
- Segmentation and analysis of the current prostate cancer pipeline by
developmental phase, drug class and company
- Insight and analysis of market potential including commercial opportunity,
epidemiology and discussion of unmet needs
Research and analysis highlights
There are 136 drugs in clinical development for prostate cancer. Molecular
targeted therapies are the predominant therapy class in the pipeline,
accounting for 47%. Cytotoxic therapies account for 19% of the pipeline, while
immunotherapies account for 21%, antihormonal therapies for 6%, gene therapies
for 5% and photodynamic therapies for 1%.
The greatest unmet need lies in treatment of castration-resistant prostate
cancer. First-line therapy revolves around Taxotere (docetaxel;
Sanofi-Aventis), however, many patients are precluded from therapy due to
toxicity concerns. Unmet needs are even higher in the second-line setting,
where there are no approved products and no standard of care.
Abiraterone (CB-7630; Cougar Biotechnology/Johnson & Johnson) is forecast to
achieve the highest sales of the late-phase prostate cancer pipeline products
by 2018. Abiraterone has shown encouraging activity in heavily pretreated
patients, which could fulfill unmet needs by providing therapy options where
there is currently no standard of care.
Key reasons to purchase this research
- Identify key drugs and companies within the prostate cancer pipeline based
on sales forecasts to 2018 and Datamonitor drug assessment
- Characterize unmet need and poorly served patient subsets within prostate
cancer and assess the potential for pipeline products to fulfill them
- Assess the shifting prostate cancer market dynamic and how future
treatment will incorporate pipeline products
| 
View Cart
